**Supplemental Digital Content 4. Clinical Response, Microbiologic Response, and Per-Pathogen Microbiologic Response at EOIV Visit (mMITT Population)**

|  |  |  |
| --- | --- | --- |
| **Outcome** | **C/T (N=71)** | **MEM (N=24)** |
| Clinical response, n (%) | 67 (94.4) | 24 (100) |
| Per-participant microbiologic response (eradication), n (%) | 68 (95.8) | 24 (100) |
| Per-pathogen microbiologic response (eradication), n/N1 (%) |  |  |
|  All Enterobacterales | 64/66 (97.0) | 22/22 (100) |
|  *Escherichia coli* | 51/53 (96.2) | 21/21 (100) |
|  *Klebsiella pneumoniae* | 6/6 (100) | 1/1 (100) |
|  *Pseudomonas aeruginosa* | 4/5 (80) | 2/2 (100) |

C/T, ceftolozane/tazobactam; CE, clinically evaluable; EOIV, end of IV therapy; MEM, meropenem; mMITT, microbiologic modified intent-to-treat, N1, number of participants in mMITT population for each specific pathogen.